Regadenoson is Safe and Reduces Systemic Inflammation Post Lung Transplantation

We hypothesized that regadenoson, an adenosine A2A receptor (A2AR)- selective agonist, will attenuate the ischemia-reperfusion injury in lung transplant recipients. Clinical trial (NCT03072589) evaluated the safety of regadenoson infusion during and after lung transplantation. Primary graft dysfunction (PGD) scores and selected molecular biomarkers were also assessed.

Source: The Journal of Heart and Lung Transplantation - April 1, 2022 Category: Transplant Surgery Authors: Y. Zhao, J. Rabin, E. Mostafa, E. Fleischmann, M. Al-Suqi, U. Dhru, M.R. Conaway, J. Linden, A.S. Krupnick, S.P. Atamas, C.L. Lau Tags: (1042) Source Type: research